SAA1 levels to predict cancer immunotherapy response
Part of Cancer, Immune system & allergy clinical trials.
This trial measures a protein called SAA1 in your blood and tumor tissue to see if it can predict how your cancer will respond to immunotherapy. It aims to understand why some patients have rapid tumor growth after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of one of the listed cancers (e.g., lung, breast, colon, head and neck, or others)
- You are scheduled to receive immunotherapy (immune checkpoint inhibitors)
- Your overall health status is good enough for daily activities (ECOG score 0 or 1)
- You do not have other active cancers (except certain cured skin or cervical cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a blood marker called SAA1 to see if it can predict how severe mouth sores (oral mucositis) will be after radiation therapy. If you have head and neck cancer and are about to get radiation, this trial may help answer questions about side effects.
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This study looks at blood samples from people with cancer who are starting immunotherapy. Researchers want to find markers that might predict how well the treatment works and whether it could cause side effects.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.